Semaglutide and weight loss – a concern for diabetics and pharmaceuticals
Madam, On 4 June 2021, the FDA approved intravenous Wegovy (semaglutide) for weight-loss management in chronically obese individuals [1]. However, Wegovy, also sold under the name Ozempic, has long been a shortcut for rapid weight loss and gained a reputation as “the worst kept secret in Hollywoo...
| 出版年: | Journal of the Pakistan Medical Association |
|---|---|
| 主要な著者: | , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Pakistan Medical Association
2024-05-01
|
| 主題: | |
| オンライン･アクセス: | https://jpma.org.pk/index.php/public_html/article/view/10705 |